Cargando…

Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC

Anti-PD-1/PD-L1 therapy indications are broadened in non-small cell lung cancer (NSCLC) although immune checkpoint inhibitors (ICI) do not provide benefits for the entire population. Texture features based on positron emission tomography/computed tomography (PET/CT), especially entropy (based on a g...

Descripción completa

Detalles Bibliográficos
Autores principales: Malet, Julie, Ancel, Julien, Moubtakir, Abdenasser, Papathanassiou, Dimitri, Deslée, Gaëtan, Dewolf, Maxime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142835/
https://www.ncbi.nlm.nih.gov/pubmed/37109580
http://dx.doi.org/10.3390/life13041051
_version_ 1785033707422220288
author Malet, Julie
Ancel, Julien
Moubtakir, Abdenasser
Papathanassiou, Dimitri
Deslée, Gaëtan
Dewolf, Maxime
author_facet Malet, Julie
Ancel, Julien
Moubtakir, Abdenasser
Papathanassiou, Dimitri
Deslée, Gaëtan
Dewolf, Maxime
author_sort Malet, Julie
collection PubMed
description Anti-PD-1/PD-L1 therapy indications are broadened in non-small cell lung cancer (NSCLC) although immune checkpoint inhibitors (ICI) do not provide benefits for the entire population. Texture features based on positron emission tomography/computed tomography (PET/CT), especially entropy (based on a gray-level co-occurrence matrix (GLCM)), could be interesting as predictors in NSCLC. The aim of our retrospective study was to evaluate the association between GLCM-entropy and response to anti-PD-1/PD-L1 monotherapy at the first evaluation in stage III or IV NSCLC, comparing patients with progressive disease (PD) and non-progressive disease (non-PD). In total, 47 patients were included. Response Evaluation Criteria in Solid Tumors (RECIST 1.1) were used to evaluate the response to ICI treatment (nivolumab, pembrolizumab, or atezolizumab). At the first evaluation, 25 patients were PD and 22 were non-PD. GLCM-entropy was not predictive of response at the first evaluation. Furthermore, GLCM-entropy was not associated with progression-free survival (PFS) (p = 0.393) or overall survival (OS) (p = 0.220). Finally, GLCM-entropy measured in PET/CT performed before ICI initiation in stage III or IV NSCLC was not predictive of response at the first evaluation. However, this study demonstrates the feasibility of using texture parameters in routine clinical practice. The interest of measuring PET/CT texture parameters in NSCLC remains to be evaluated in larger prospective studies.
format Online
Article
Text
id pubmed-10142835
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101428352023-04-29 Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC Malet, Julie Ancel, Julien Moubtakir, Abdenasser Papathanassiou, Dimitri Deslée, Gaëtan Dewolf, Maxime Life (Basel) Article Anti-PD-1/PD-L1 therapy indications are broadened in non-small cell lung cancer (NSCLC) although immune checkpoint inhibitors (ICI) do not provide benefits for the entire population. Texture features based on positron emission tomography/computed tomography (PET/CT), especially entropy (based on a gray-level co-occurrence matrix (GLCM)), could be interesting as predictors in NSCLC. The aim of our retrospective study was to evaluate the association between GLCM-entropy and response to anti-PD-1/PD-L1 monotherapy at the first evaluation in stage III or IV NSCLC, comparing patients with progressive disease (PD) and non-progressive disease (non-PD). In total, 47 patients were included. Response Evaluation Criteria in Solid Tumors (RECIST 1.1) were used to evaluate the response to ICI treatment (nivolumab, pembrolizumab, or atezolizumab). At the first evaluation, 25 patients were PD and 22 were non-PD. GLCM-entropy was not predictive of response at the first evaluation. Furthermore, GLCM-entropy was not associated with progression-free survival (PFS) (p = 0.393) or overall survival (OS) (p = 0.220). Finally, GLCM-entropy measured in PET/CT performed before ICI initiation in stage III or IV NSCLC was not predictive of response at the first evaluation. However, this study demonstrates the feasibility of using texture parameters in routine clinical practice. The interest of measuring PET/CT texture parameters in NSCLC remains to be evaluated in larger prospective studies. MDPI 2023-04-20 /pmc/articles/PMC10142835/ /pubmed/37109580 http://dx.doi.org/10.3390/life13041051 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Malet, Julie
Ancel, Julien
Moubtakir, Abdenasser
Papathanassiou, Dimitri
Deslée, Gaëtan
Dewolf, Maxime
Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC
title Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC
title_full Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC
title_fullStr Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC
title_full_unstemmed Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC
title_short Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC
title_sort assessment of the association between entropy in pet/ct and response to anti-pd-1/pd-l1 monotherapy in stage iii or iv nsclc
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142835/
https://www.ncbi.nlm.nih.gov/pubmed/37109580
http://dx.doi.org/10.3390/life13041051
work_keys_str_mv AT maletjulie assessmentoftheassociationbetweenentropyinpetctandresponsetoantipd1pdl1monotherapyinstageiiiorivnsclc
AT anceljulien assessmentoftheassociationbetweenentropyinpetctandresponsetoantipd1pdl1monotherapyinstageiiiorivnsclc
AT moubtakirabdenasser assessmentoftheassociationbetweenentropyinpetctandresponsetoantipd1pdl1monotherapyinstageiiiorivnsclc
AT papathanassioudimitri assessmentoftheassociationbetweenentropyinpetctandresponsetoantipd1pdl1monotherapyinstageiiiorivnsclc
AT desleegaetan assessmentoftheassociationbetweenentropyinpetctandresponsetoantipd1pdl1monotherapyinstageiiiorivnsclc
AT dewolfmaxime assessmentoftheassociationbetweenentropyinpetctandresponsetoantipd1pdl1monotherapyinstageiiiorivnsclc